Muzaffar Qazilbash, Director of Myeloma Transplantation and Cellular Therapy at MD Anderson Cancer Center, shared on X:
“Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality or Sequential Strategies in RRMM. Retrospective data from 640 patients. Conclusion: Use both, but CAR-T (mainly cilta-cel) first due to longer PFS.”
Title: Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Authors: Maximilian Merz, Tomas Jelinek, Thomas Pabst, Raphael Teipel, Anca-Maria Albici, Bastian von Tresckow, Marcel Teichert, Uta Margareta Demel, Antonia Busse, Marie Christine Wesener, Tobias A. W. Holderried, Friederike Schmitz,
Friedrich-Linus Rößiger, Fabian Müller, Michele Hoffmann, Friedrich Stölzel, Natalia Tovar, Ben-Niklas Baermann, Martin Stork, Alexandra Jungova, Jiri Minarik, Jakub Radocha, Ivan Spicka, Ludek Pour, Polona Novak, Klara Slajpah, Karla Rener, Ulrich Keller, Stephan Bohl, David Fandrei, Patrick Born, Vladan Vucinic, Nicolaus Kröger, Irene Strassl, Natalie Schub, Roman Hájek, Matjaz Sever, Carlos Fernández de Larrea, Nico Gagelmann
